ClinicalTrials.gg
CompletedNCT02797977Updated Jun 22, 2023

A Phase 1/2 Trial SRA737 in Combination With Gemcitabine and Cisplatin or Gemcitabine Alone in Advanced Cancer Subjects

A Phase 1/2 interventional study of SRA737, gemcitabine, cisplatin and SRA737, gemcitabine in Advanced Solid Tumors, sponsored by Sierra Oncology LLC - a GSK company. Completed at 20 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Sierra Oncology LLC - a GSK company (part of GlaxoSmithKline) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
153
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this clinical study is to establish the safety profile, determine the maximum tolerated dose (MTD) and recommend a Phase 2 dose (RP2D) and schedule of SRA737 in combination with low dose gemcitabine; and to evaluate the efficacy of SRA737 in combination with low dose gemcitabine in prospectively-selected subjects with genetically-defined tumors that have predicted sensitivity to Chk1 inhibition based on factors including: genetic profiling of tumor tissue or ctDNA, HPV status, and germline BRCA1 and BRCA2 gene status. Specific cancer indications that frequently feature these factors will be studied.

Preclinical and clinical data support the hypothesis that active doses of SRA737 may be strongly potentiated by sub-therapeutic doses of gemcitabine, which should lead to clinical efficacy. To test this hypothesis, SRA737 in combination with low dose gemcitabine is being explored in this study.

Read the detailed description

SRA737 is a potent, highly selective, orally bioavailable small molecule inhibitor of Chk1, a key regulator of cell cycle progression and the DNA Damage Response (DDR) replication stress response. In cancer cells, intrinsic replication stress (RS) is induced by factors such as oncogenes (e.g., CCNE1 or MYC), genetic mutations in DNA repair machinery (e.g., BRCA1 or FA), genetic mutations leading to a dysregulated cell cycle (e.g., TP53 or RAD50) or other genomic alterations. This replication stress results in persistent DNA damage and genomic instability leading to an increased dependency on Chk1 for survival. Targeted inhibition of Chk1 by SRA737 may therefore be synthetically lethal to cancer cells with elevated intrinsic RS.

The critical role of Chk1 in mediating cellular responses to RS affords the opportunity to combine SRA737 with sub-therapeutic concentrations of the RS-inducing agent gemcitabine. Low concentrations of gemcitabine cause a prolonged cell cycle S-phase and induce hallmarks of RS without inducing overt cytotoxicity. Gemcitabine profoundly depletes DNA replication building blocks and targets proliferating cells by inducing RS through induction of stalled replication forks. In response, Chk1 has an important role in stabilizing and preserving replication fork complexes in the context of RS, preventing catastrophic replication fork collapse and double strand breaks. Extensive preclinical data, as well as clinical data, support the synergistic interaction between Chk1 inhibition and gemcitabine.

The purpose of this clinical study is to: establish the safety profile, determine the MTD, and propose a RP2D and schedule for SRA737 in combination with low dose gemcitabine. In addition, the study aims to evaluate the preliminary efficacy of SRA737 in combination with low dose gemcitabine in prospectively-selected subjects with tumors that have predicted sensitivity to Chk1 inhibition.

This clinical study consists of three phases:

  1. A Standard-Dose Triplet Combo Dose Escalation Phase 1. This phase, which has concluded, evaluated a triplet combination of SRA737 with standard-dose gemcitabine and cisplatin in subjects with solid tumors.
  2. A Low-Dose Gemcitabine Combo Dose Escalation Phase 1. Cohorts of 3 to 6 subjects are being given escalating doses of SRA737 on an intermittent schedule in addition to low dose gemcitabine until the combination MTD is reached. The dose or frequency of gemcitabine may also be reduced during this process and alternative dosing schedules for SRA737 may be considered. When the MTD or a minimum efficacious dose range has been achieved for SRA737, or when evidence of anti-tumor activity is observed, the gemcitabine dose may be escalated with corresponding decreases in the SRA737 dose as necessary for safety.
  3. A Low-Dose Gemcitabine Combo Cohort Expansion Phase 2. After the MTD and/or RP2D has been identified, the trial will explore the preliminary efficacy of SRA737 plus low dose gemcitabine in prospectively-selected subjects with tumors that harbor genomic alterations linked to increased replication stress and that are hypothesized to be more sensitive to Chk1 inhibition via synthetic lethality. Enrollment for expansion cohorts may alternatively begin prior to the completion of dose escalation and determination of MTD or RP2D, if there is evidence of anti-tumor activity or if the minimal plasma concentration of SRA737 is maintained above a threshold at which sustained Chk1 inhibition is anticipated at 24 hours after dosing.

This phase is targeting enrollment of genetically-selected patients into four expansion cohorts from specific indications that are predicted to have a high prevalence of such alterations, including locally advanced or metastatic:

  • high-grade serous ovarian cancer (HGSOC),
  • small cell lung cancer (SCLC);
  • soft tissue sarcoma (STS); and
  • cervical/anogenital cancer.

To qualify for enrolment into these cohorts, the subject's tumor must have evidence of predicted sensitivity to Chk1 inhibition based on factors including:

  • For subjects with HGSOC, documented somatic or germline BRCA1 and BRCA2 wild-type status will confer eligibility without requirement for prospective genetic profiling. If documented BRCA status is not available, genetic profiling may be performed prospectively to determine eligibility.
  • Subjects with SCLC are eligible without requirement for prospective genetic profiling on the basis of very high prevalence of cancer related alterations in the tumor suppressor genes (eg, TP53 and RB1) in this population.
  • For subjects with STS, and any others for whom genetic profiling is performed prospectively, eligibility will be determined by the sponsor's review of genetic abnormalities detected in genes in the following categories:

    • Key tumor suppressor genes regulating G1 cell cycle progression/arrest such as RB1, TP53, etc.
    • The DNA damage response pathway including ATM, BRCA1, BRCA2, mismatch repair genetic alterations and/or high microsatellite instability.
    • Genetic indicators of replicative stress such as gain of function/amplification of Chk1 or ATR or other related gene.
    • Oncogenic drivers such as MYC, CCNE1, etc.
  • For subjects with anogenital cancer, known HPV positive status will confer eligibility without requirement for prospective genetic profiling. If HPV status is not known or not positive, genetic profiling (or HPV testing where appropriate) may be performed prospectively to determine eligibility. Subjects with cervical cancer or squamous cell carcinoma of the anus are eligible without requirement for prospective genetic profiling based on the very high prevalence of HPV positivity in these populations.

Tumor genetics will be determine using Next-Generation Sequencing.

02

Conditions studied

  • Advanced Solid Tumors

Keywords

  • Replication Stress
  • Advanced solid tumors
  • CCNE1
  • TP53
  • BRCA1
  • BRCA2
  • MYC
  • RAD50
  • Fanconi anemia
  • Cell Cycle
  • High grade serious ovarian cancer
  • Small cell lung cancer
  • Soft tissue sarcoma
  • Cervical/anogenital cancer
  • Phase 1
  • Phase 2
  • Dose escalation
  • Chk1 inhibitor
  • Checkpoint Kinase 1
  • Synthetic lethality
  • Next-Generation Sequencing
  • Genetic biomarkers
03

In context

Fanconi Anemia

95 studies on the registry are indexed under Fanconi Anemia; 20 are open to participants now.

This study's enrollment of 153 is above the median of 21 across 61 interventional studies indexed under Fanconi Anemia.

Browse Fanconi Anemia studies →

Lead sponsor

Sierra Oncology LLC - a GSK company is the lead sponsor of 19 studies on the registry; none are open to participants now.

Of its 8 completed or terminated interventional studies of FDA-regulated products, 5 (63%) have results posted.

First submitted before Sierra Oncology LLC became part of GlaxoSmithKline.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. For Dose Escalation: subjects with locally advanced or , or cytologically proven solid tumor, after or progressing despite conventional treatment
  2. of at least 12 weeks
  3. World Health Organization (WHO) performance status of 0-1
  4. Must meet select hematological and biochemical laboratory indices
  5. or accessible tumor and willingness to consent to a biopsy

Expansion Only:

  1. Histologically or cytologically proven advanced of the following types, for which no other conventional therapy is considered appropriate:

    • High-grade serous ovarian cancer (HGSOC)
    • Small cell lung cancer
    • Soft tissue sarcoma
    • Cervical/anogenital cancer
  2. per v1.1
  3. Subjects must have predicted sensitivity to Chk1 inhibition based on factors including: genetic profiling of tumor tissue or ctDNA, HPV status, and germline BRCA1 and BRCA2 gene status. All subjects will have genetic profiling from tumor tissue or ctDNA; profiling will be performed prospectively if required to evaluate Chk1 sensitivity or otherwise performed retrospectively.

    1. For subjects with HGSOC, documented somatic or germline BRCA1 and BRCA2 wild-type status will confer eligibility without requirement for prospective genetic profiling. If documented BRCA status is not available, genetic profiling may be performed prospectively to determine eligibility.
    2. Subjects with SCLC are eligible without requirement for prospective genetic profiling on the basis of very high prevalence of cancer related alterations in the tumor suppressor genes (eg, TP53 and RB1) in this population.
    3. For subjects with STS, and any others for whom genetic profiling is performed prospectively, eligibility will be determined by the sponsor's review of genetic abnormalities detected in genes in the following categories:

      Key tumor suppressor genes regulating G1 cell cycle progression/arrest such as RB1, TP53, etc. For relevant cancers, positive human papilloma virus (HPV) status is also considered for eligibility.

      • The DNA damage response pathway including ATM, BRCA1, BRCA2, mismatch repair genetic alterations and/or high microsatellite instability.
      • Genetic indicators of replicative stress such as gain of function/amplification of Chk1 or ATR or other related gene.
      • Oncogenic drivers such as MYC, CCNE1, etc.
    4. For subjects with anogenital cancer, known HPV positive status will confer eligibility without requirement for prospective genetic profiling. If HPV status is not known or not positive, genetic profiling (or HPV testing where appropriate) may be performed prospectively to determine eligibility. Subjects with cervical cancer or squamous cell carcinoma of the anus are eligible without requirement for prospective genetic profiling based on the very high prevalence of HPV positivity in these populations.

Key Exclusion Criteria:

  1. Received the following prior or current anticancer therapy in the timeframes noted prior to receiving SRA737 and have recovered from toxicity:

    1. Radiotherapy, chemotherapy, PARP inhibitors, other targeted therapies, or other IMPs within 2 weeks
    2. Nitrosoureas or Mitomycin C within 6 weeks
    3. Any prior treatment with a Chk1 inhibitor at any point or prior treatment with an ATR inhibitor within 6 months
  2. No more than 3 previous treatment regimens for advanced disease (not applicable to HGSOC expansion cohort)
  3. Other malignancy within the past 2 years, except for adequately treated tumors
  4. If, in the opinion of the Investigator, the subject is highly likely to experience myelosuppression
  5. Ongoing toxic manifestations of previous treatments greater than Grade 1
  6. History of allergy to gemcitabine
  7. New or progressing . Subjects with brain metastases that have been asymptomatic and radiologically stable over an 8-week period and have not been treated with during that time may be included with approval from the sponsor.
  8. High medical risk because of nonmalignant systemic disease
  9. Serologically positive for , or
  10. Serious cardiac condition, \< 45% at baseline, history of cardiac ischemia within the past 6 months, or prior history of cardiac arrhythmia requiring treatment, unless approved by the sponsor.
  11. Prior bone marrow transplant or extensive radiotherapy to greater than 25% of bone marrow within the previous 8 weeks
  12. Peanut allergy
  13. > 450 msec in adult makes and > 470 msec in adult females
  14. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of SRA737
  15. Inability to swallow capsules without chewing or crushing
  16. Is a participant or plans to participate in another interventional clinical trial
  17. Any other condition which in the Investigator's opinion would not make the subject a good candidate
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
153 participants (actual)

Study arms

  • Experimental
    Standard-Dose Triplet Combination

    SRA737 will be administered orally on Days 2, 3, 9, and 10 of each 21-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Gemcitabine will be administered intravenously on Days 1 and 8 of each 21-day cycle. Cisplatin will be administered on Day 1 of each 21-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study.

    Drug: SRA737, gemcitabine, cisplatin

  • Experimental
    Low-Dose Gemcitabine Combination

    SRA737 will be administered orally on Days 2, 3, 9, 10, 16, and 17 of each 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle. Gemcitabine will be administered intravenously on Days 1, 8, and 15 of each 28-day cycle. Subjects can continue taking the study treatment if they are safely receiving clinical benefit and able to follow the requirements of the study.

    Drug: SRA737, gemcitabine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of subjects with adverse events as assessed by CTCAE4.03

    Time frame: Up to 30 days after last dose of SRA737

  2. Maximum tolerated dose of SRA737 administered in combination with gemcitabine

    Time frame: Cycle 1 (28 days) in the Dose Escalation Phase

  3. Recommended Phase 2 dose of SRA737 in combination with gemcitabine.

    Time frame: Up to 30 days after last dose of SRA737

07

Study locations

20 sites
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 08036, Spain
  • START Madrid
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octobre
    Madrid, 28041, Spain
  • Hospital Universitario Virgen de la Victoria
    Málaga, 29010, Spain
  • Biomedical Research Institute INCLIVA
    Valencia, 46010, Spain
  • Royal Marsden Hospital
    Sutton, London SM2 5PT, United Kingdom
  • Belfast City Hospital
    Belfast, Northern Ireland BT9 7AB, United Kingdom
  • Oxford University Hospitals
    Headington, Oxford OX3 7LE, United Kingdom
  • Velindre Cancer Centre
    Cardiff, Whitchurch CF14 2TL, United Kingdom
  • The Clatterbridge Cancer Centre
    Bebington, Wirral CH63 4JY, United Kingdom
  • The Beatson West of Scotland Cancer Centre
    Glasgow, G12 0YN, United Kingdom
  • Leeds Teaching Hospital of St James University Hospital
    Leeds, LS9 7TF, United Kingdom
  • University Hospital of Leceister NHS TRUST
    Leicester, LE1 5WW, United Kingdom
  • Guy's and St Thomas'
    London, SE1 9RT, United Kingdom
  • Sarah Cannon Research Institute
    London, W1G 6AD, United Kingdom
  • University College London
    London, WC1E 6BT, United Kingdom
  • The Christie NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
  • Freeman Hospital
    Newcastle upon Tyne, NE7 7DN, United Kingdom
  • Sheffield Teaching Hospitals
    Sheffield, S10 2SJ, United Kingdom
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2016 to primary completion in Apr 2020, 45 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 23, 2016
First posted
Jun 14, 2016
StartActual
Jul 2016
Primary completionActual
Apr 8, 2020
CompletionActual
Apr 8, 2020
Last update
Jun 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02797977
Responsible party
Sponsor
First posted
Jun 14, 2016
Start date
Jul 2016
Primary completion
Apr 8, 2020
Completion
Apr 8, 2020
Last update
Jun 22, 2023

Study contacts

Study Director
study director · Sierra Oncology LLC - a GSK company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Gemcitabine · Cisplatin

Start the discussion